Medication info
Gabanyuro Capsule 75 mg (Pregabalin)

Gabanyuro Capsule 75 mg (Pregabalin)

Prescription medicationHard capsuleOral
Ingredient · strength
Pregabalin›75mg / 1 capsule
Manufacturer / importer
Hankook Pharmaceutical Co., Ltd.
Appearance
Hard capsule with a brown-red upper part and white lower part containing white or pale yellow powder
Packaging
30 capsules/bottle, 100 capsules/bottle
Approval status
Active

MFDS item code 201109274 · Notified 2011.10.31 · Insurance code 645304380

Summary

Main use
Treatment of neuropathic pain, adjunctive treatment of partial-onset seizures in epilepsy, treatment of fibromyalgia
Who takes it
Adults · Children
Adult dose
This medicine is administered orally, with or without food, as the total daily dose of pregabalin divided into 2 doses. Since this medicine is primarily excreted by the kidneys, the dose should be adjusted in patients with impaired renal function. (See section ‘5. Patients with Renal Impairment’) 1. Neuropathic pain 1) Peripheral neuropathic pain Adults: This medicine may be administered at an initial dose of 150 mg/day. Based on each patient’s response and tolerability, the dose may be increased to 300 mg/day after 3 to 7 days. If necessary, it may subsequently be increased at 7-day intervals to a maximum of 600 mg/day. 2) Central neuropathic pain Adults: This medicine may be administered at an initial dose of 150 mg/day. Based on each patient’s response and tolerability, the dose may be increased to 300 mg/day after 1 week. After an additional 1 week, it may be increased to the target daily dose of 600 mg. If the target daily dose is not tolerated, dose reduction may be considered. (See section ‘4. Discontinuation of Treatment’) 2. Epilepsy Adults: This medicine may be administered at an initial dose of 150 mg/day. Based on each patient’s response and tolerability, the dose may be increased to 300 mg/day after 1 week. If necessary, it may subsequently be increased at 7-day intervals to a maximum of 600 mg/day. 3. Fibromyalgia The recommended dose of this medicine for fibromyalgia is 300 mg to 450 mg/day. The initial dose is 75 mg twice daily (150 mg/day), which may be increased to 150 mg twice daily (300 mg/day) within 1 week based on efficacy and tolerability. For patients who do not experience sufficient benefit at a dose of 300 mg/day, the dose may be increased to 225 mg twice daily (450 mg/day) within 1 week. Clinical studies have also been conducted at a dose of 600 mg/day; however, there is no evidence of additional benefit or adequate tolerability at this dose. In view of dose-dependent adverse reactions, doses exceeding 450 mg/day are not recommended. 4. Discontinuation of Treatment Based on current clinical experience, if treatment with this medicine is discontinued, it should be tapered gradually over at least 1 week. 5. Patients with Renal Impairment After entering the systemic circulation, this medicine is primarily excreted by the kidneys unchanged. Since the clearance of this medicine is directly affected by creatinine clearance, dose reduction in patients with impaired renal function should be individualized based on creatinine clearance. Creatinine clearance [Table 1] is determined using the following formula. Creatinine clearance (mL/min)* = [140-age (years)] × body weight (kg)/72 × serum creatinine concentration (serum creatinine, mg/dL) *: For women, multiply the result obtained using the above formula by 0.85. This medicine is effectively removed from plasma by hemodialysis (approximately 50% within 4 hours). In patients undergoing hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose based on renal function, a supplemental dose should be administered immediately after every 4 hours of hemodialysis. [Table 1]. Pregabalin dosage based on renal function Creatinine clearance (CLcr), (mL/min) Total daily dose of pregabalin a Dosage regimen Starting dose (mg/day) Maximum dose (mg/day) ≥60 150 600 BID or TID ≥30 -<60 75 300 BID or TID ≥15 -<30 25-50 150 QD or BID <15 25 75 QD Supplemental dose after hemodialysis 25 100 Single dose b TID = total daily dose administered in 3 divided doses BID = total daily dose administered in 2 divided doses QD = administered once daily a: The total daily dose (mg/day) should be administered in divided doses as specified in the dosage regimen. b: Supplemental dose refers to a dose administered as a single additional dose. 6. Patients with Hepatic Impairment Dose adjustment is not necessary in patients with hepatic impairment. 8. Elderly patients (65 years of age or older) Dose reduction may be necessary in elderly patients with impaired renal function.
Child dose
Children under 12 years of age: Administration is not recommended because there are insufficient data on safety and efficacy. Adolescent patients aged 12 ~17 years: Administration is not recommended because there are insufficient data on safety and efficacy.

Ingredients

Manufacturer
Hankook Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of neuropathic pain, adjunctive treatment of partial-onset seizures in epilepsy, treatment of fibromyalgia

  • Peripheral neuropathic pain
  • central neuropathic pain
  • partial seizures
  • fibromyalgia
View approved original text

This drug is used to treat peripheral and central neuropathic pain in adults and is also used as an adjunct treatment for partial seizures, which are part of epilepsy. It also helps alleviate symptoms in fibromyalgia patients. In other words, it is effective for the treatment of nerve-related pain, certain seizures, and chronic muscle pain.

How to take

Adult dose

This medicine is administered orally, with or without food, as the total daily dose of pregabalin divided into 2 doses. Since this medicine is primarily excreted by the kidneys, the dose should be adjusted in patients with impaired renal function. (See section ‘5. Patients with Renal Impairment’) 1. Neuropathic pain 1) Peripheral neuropathic pain Adults: This medicine may be administered at an initial dose of 150 mg/day. Based on each patient’s response and tolerability, the dose may be increased to 300 mg/day after 3 to 7 days. If necessary, it may subsequently be increased at 7-day intervals to a maximum of 600 mg/day. 2) Central neuropathic pain Adults: This medicine may be administered at an initial dose of 150 mg/day. Based on each patient’s response and tolerability, the dose may be increased to 300 mg/day after 1 week. After an additional 1 week, it may be increased to the target daily dose of 600 mg. If the target daily dose is not tolerated, dose reduction may be considered. (See section ‘4. Discontinuation of Treatment’) 2. Epilepsy Adults: This medicine may be administered at an initial dose of 150 mg/day. Based on each patient’s response and tolerability, the dose may be increased to 300 mg/day after 1 week. If necessary, it may subsequently be increased at 7-day intervals to a maximum of 600 mg/day. 3. Fibromyalgia The recommended dose of this medicine for fibromyalgia is 300 mg to 450 mg/day. The initial dose is 75 mg twice daily (150 mg/day), which may be increased to 150 mg twice daily (300 mg/day) within 1 week based on efficacy and tolerability. For patients who do not experience sufficient benefit at a dose of 300 mg/day, the dose may be increased to 225 mg twice daily (450 mg/day) within 1 week. Clinical studies have also been conducted at a dose of 600 mg/day; however, there is no evidence of additional benefit or adequate tolerability at this dose. In view of dose-dependent adverse reactions, doses exceeding 450 mg/day are not recommended. 4. Discontinuation of Treatment Based on current clinical experience, if treatment with this medicine is discontinued, it should be tapered gradually over at least 1 week. 5. Patients with Renal Impairment After entering the systemic circulation, this medicine is primarily excreted by the kidneys unchanged. Since the clearance of this medicine is directly affected by creatinine clearance, dose reduction in patients with impaired renal function should be individualized based on creatinine clearance. Creatinine clearance [Table 1] is determined using the following formula. Creatinine clearance (mL/min)* = [140-age (years)] × body weight (kg)/72 × serum creatinine concentration (serum creatinine, mg/dL) *: For women, multiply the result obtained using the above formula by 0.85. This medicine is effectively removed from plasma by hemodialysis (approximately 50% within 4 hours). In patients undergoing hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose based on renal function, a supplemental dose should be administered immediately after every 4 hours of hemodialysis. [Table 1]. Pregabalin dosage based on renal function Creatinine clearance (CLcr), (mL/min) Total daily dose of pregabalin a Dosage regimen Starting dose (mg/day) Maximum dose (mg/day) ≥60 150 600 BID or TID ≥30 -<60 75 300 BID or TID ≥15 -<30 25-50 150 QD or BID <15 25 75 QD Supplemental dose after hemodialysis 25 100 Single dose b TID = total daily dose administered in 3 divided doses BID = total daily dose administered in 2 divided doses QD = administered once daily a: The total daily dose (mg/day) should be administered in divided doses as specified in the dosage regimen. b: Supplemental dose refers to a dose administered as a single additional dose. 6. Patients with Hepatic Impairment Dose adjustment is not necessary in patients with hepatic impairment. 8. Elderly patients (65 years of age or older) Dose reduction may be necessary in elderly patients with impaired renal function.

Child dose

Children under 12 years of age: Administration is not recommended because there are insufficient data on safety and efficacy. Adolescent patients aged 12 ~17 years: Administration is not recommended because there are insufficient data on safety and efficacy.

Precautions

This medication is used to treat neurological disorders and may cause serious mental health issues such as suicidal thoughts or behavior, so careful monitoring for mood changes or depressive symptoms is necessary during treatment. It should not be administered to patients with hypersensitivity to this medication or specific metabolic disorders. Diabetic patients may need adjustments in their diabetes management medications due to weight gain, and if allergic reactions such as angioedema occur, treatment should be discontinued immediately. Elderly patients may be more susceptible to side effects such as dizziness, drowsiness, and confusion, and may experience visual changes such as blurred vision. Abrupt discontinuation of this medication can result in withdrawal symptoms such as insomnia, headache, and anxiety, so it should be gradually reduced in consultation with healthcare professionals. Patients with a history of substance abuse should be particularly cautious as this medication has a risk of abuse, and signs of drug misuse or dependency should be monitored during treatment. It should be administered with caution in patients with heart disease, and caution is needed when taken with opioid analgesics, as it may significantly enhance central nervous system depression. This drug may cause dizziness and drowsiness, so caution is advised when driving or operating hazardous machinery. Pregnant women should be especially cautious during early pregnancy as it may pose risks to the fetus, and women who are pregnant or planning to become pregnant should consult their doctor and use effective contraception. Breastfeeding women should consult with their healthcare provider regarding the possibility of this drug being transmitted through breast milk and may need to discontinue either breastfeeding or the medication. In cases of overdose, symptoms such as confusion, drowsiness, and seizures may occur, and emergency treatment such as hemodialysis may be necessary if needed. Keep out of reach of children and take care not to transfer the medication to another container, as this can cause accidents.

Side effects

  • suicidal ideation
  • suicidal behavior
  • depression
  • abnormal mood and behavioral changes
  • angioedema
  • facial edema
  • perioral edema
  • upper airway edema
  • dizziness
  • drowsiness
Show 179 more
  • loss of consciousness
  • confusion
  • mental disorder
  • blurred vision
  • vision changes
  • insomnia
  • headache
  • nausea
  • anxiety
  • diarrhea
  • influenza-like syndrome
  • restlessness
  • depression
  • suicidal thoughts
  • pain
  • seizures
  • hyperhidrosis
  • misuse
  • abuse
  • dependence
  • congestive heart failure
  • severe respiratory depression
  • rhinitis
  • neutropenia
  • increased appetite
  • decreased appetite
  • hypoglycemia
  • confusion
  • spatial disorientation
  • irritability
  • euphoria
  • decreased libido
  • depersonalization
  • paraphilia
  • agitation
  • mood swings
  • emotional blunting
  • emotional elevation
  • hallucinations
  • abnormal dreams
  • increased libido
  • panic attacks
  • impulsivity
  • flat affect
  • ataxia
  • motor coordination impairment
  • balance disorder
  • amnesia
  • attention disorder
  • memory impairment
  • tremor
  • dysarthria
  • sensory disturbances
  • sensory loss
  • sedation
  • somnolence
  • cognitive impairment
  • nystagmus
  • speech disorder
  • chorea
  • reflex decrease
  • motor abnormalities
  • psychomotor agitation
  • position-induced dizziness
  • perceptual sensitivity
  • burning sensation
  • action tremor
  • syncope
  • stupor
  • hypomobility syndrome
  • olfactory disturbance
  • loss of taste
  • writing disability
  • diplopia
  • vertigo
  • hyperacusis
  • first-degree AV block
  • tachycardia
  • sinus bradycardia
  • sinus tachycardia
  • sinus arrhythmia
  • hypotension
  • hypertension
  • flushing
  • facial flushing
  • peripheral coldness
  • breathlessness
  • epistaxis
  • cough
  • nasal congestion
  • rhinitis
  • snoring
  • pharyngeal tension
  • nasal dryness
  • respiratory depression
  • vomiting
  • abdominal distension
  • constipation
  • dry mouth
  • bloating
  • hypersalivation
  • gastroesophageal reflux disease
  • oral sensory loss
  • ascites
  • dysphagia
  • pancreatitis
  • sweating
  • papular rash
  • urticaria
  • cold sweats
  • muscle cramps
  • arthralgia
  • back pain
  • limb pain
  • cervical spasm
  • joint swelling
  • myalgia
  • muscle spasm
  • neck pain
  • muscle rigidity
  • rhabdomyolysis
  • urination disorders
  • urinary incontinence
  • reduced urination
  • renal failure
  • erectile dysfunction
  • delayed ejaculation
  • sexual dysfunction
  • dysmenorrhea
  • amenorrhea
  • breast pain
  • nipple discharge
  • breast enlargement
  • peripheral edema
  • edema
  • gait disturbance
  • falls
  • feeling of intoxication
  • sensation anomalies
  • fatigue
  • chest tightness
  • generalized edema
  • pain
  • fever
  • chills
  • weakness
  • thirst
  • weight gain
  • increased alanine aminotransferase
  • increased serum creatine phosphokinase
  • increased aspartate aminotransferase
  • increased blood sugar
  • decreased platelet count
  • decreased serum potassium
  • weight loss
  • increased serum creatinine
  • decreased white blood cell count
  • hypersensitivity
  • allergic reaction
  • headache
  • keratitis
  • pulmonary edema
  • nausea
  • diarrhea
  • tongue swelling
  • itching
  • Stevens-Johnson syndrome
  • toxic epidermal necrolysis
  • urinary retention
  • gynecomastia
  • lethargy
  • delirium
  • paralysis (facial paralysis)
  • affective disorder
  • drowsiness
  • state of confusion
  • agitation
  • restlessness
  • worsening of seizures

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly closed container to protect it from air and moisture, and it is recommended to store it at room temperature between 15°C and 30°C. By storing it this way, the effectiveness of the medication can be maintained for a long time.

Appearance and packaging

Appearance

Hard capsule with a brown-red upper part and white lower part containing white or pale yellow powder

Package unit

30 capsules/bottle, 100 capsules/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.